

UBS AG  
Form 424B3  
November 01, 2018

**Filed Pursuant to Rule 424(b)(3)  
Registration No. 333-225551**

## **PROSPECTUS ADDENDUM**

**(to Prospectus Supplements dated as of various dates, and Prospectus dated  
October 31, 2018)**

**UBS AG**

### **Exchange Traded Access Securities (ETRACS) Series B**

This prospectus addendum relates to various series of outstanding Exchange Traded Access Securities (collectively, ETRACS ) previously issued by UBS AG that are part of a series of debt securities entitled Medium Term Notes, Series B . This prospectus addendum and the applicable prospectus supplement, dated as of various dates, will be used by UBS AG in connection with the continuous offering of outstanding series of previously issued ETRACS. The ETRACS were initially registered, and all or a portion were initially offered and sold, under registration statements previously filed by UBS AG. When UBS AG initially registered your series of ETRACS, UBS AG prepared a prospectus supplement (as amended or supplemented from time to time), each referred to as the original prospectus supplement , relating to your series of ETRACS. The applicable original prospectus supplement relating to each series of ETRACS is attached to a base prospectus, which has been replaced from time to time, most recently by a base prospectus dated April 29, 2016.

UBS AG has prepared a new base prospectus dated October 31, 2018. This new base prospectus replaces the base prospectus dated April 29, 2016. Because the terms of your ETRACS otherwise have remained the same, UBS AG is continuing to use the original prospectus supplement. As a result, you should read the original prospectus supplement for your ETRACS, which gives the specific terms of your ETRACS, together with the base prospectus dated October 31, 2018. When you read these documents, please note that all references in the original prospectus supplement to the base prospectus dated as of a date prior to October 31, 2018, or to any sections of the prior base prospectus, should refer instead to the base prospectus dated October 31, 2018, or to the corresponding section of that base prospectus. In addition, please note that instead of using the website links in the original prospectus supplement to the base prospectus dated as of a date prior to October 31, 2018, you should use the following website link to access the base prospectus dated October 31, 2018.

<http://www.sec.gov/Archives/edgar/data/1114446/000119312518314003/d612032d424b3.htm>

In addition, please disregard the table of contents for the base prospectus dated as of a date prior to October 31, 2018 that is provided in the original prospectus supplement for your securities. A table of contents for the new base prospectus is provided on page i of the October 31, 2018 base prospectus.

### **Supplemental Risk Factor Disclosure**

***Differences between the Securities and Bank Deposits***

An investment in the Securities may give rise to higher yields than a bank deposit placed with UBS or with any other investment firm in the UBS Group (a UBS Bank Deposit ). However, an investment in the Securities carries risks which are very different from the risk profile of a UBS Bank Deposit. The Securities are expected to have greater liquidity than a UBS Bank Deposit since UBS Bank Deposits are generally not transferable. However, the Securities may have no established trading market when issued, and one may never develop. Investments in the Securities do not benefit from the protection provided pursuant to Directive 2014/49/EU of the European Parliament and of the Council of the European Union on deposit guarantee schemes or any national implementing measure implementing this Directive in any jurisdiction. Therefore, if we become insolvent or default on our obligations, investors investing in such Securities in a worst case scenario could lose their entire investment. Further, if UBS experiences financial difficulties, the Swiss Financial Market Supervisory Authority has the power to open resolution or liquidation proceedings or impose protective measures in relation to UBS Group AG, UBS AG or UBS Switzerland AG, and holders of the Securities may be subject to write-down or conversion into equity on any application of the general bail-in tool and non-viability loss absorption, which may result in such holders losing some or all of their investment.

**PROHIBITION OF SALES TO EEA RETAIL INVESTORS** The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area ( EEA ). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, MiFID II ); (ii) a customer within the meaning of Directive 2002/92/EC (as amended, the Insurance Mediation Directive ), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined in Directive 2003/71/EC (as amended, the Prospectus Directive ). Consequently no key information document required by Regulation (EU) No 1286/2014 (the PRIIPs Regulation ) for offering or selling the Securities or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Securities or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.

UBS AG, UBS Securities LLC, UBS Financial Services Inc. or any affiliate of UBS AG may use this prospectus addendum, together with the original prospectus supplements and the new base prospectus, in connection with offers and sales of the ETRACS in market-making transactions. Please see Supplemental Plan of Distribution in the original prospectus supplement for your ETRACS and Plan of Distribution in the new base prospectus.

**UBS Investment Bank**

**UBS Financial Services Inc.**

**Prospectus Addendum dated October 31, 2018**